Johnson & Johnson: A Steady Healthcare Blue Chip for Income and Resilience

# Johnson & Johnson Stock Analysis: Near Record Highs with Strong Oncology Growth In this episode, we dive into Johnson & Johnson (JNJ) as it trades near its 52-week high of $207, currently hovering around $202. With a market cap approaching $486 billion, JNJ shows powerful upward momentum in 2025, supported by both 50-day and 200-day moving averages confirming a bullish trend. ## Key Highlights: - Impressive Phase 3 Mariposa study results showing significant survival benefits for lung cancer therapy Rybrevant combined with Lazcluze - Strong performance from Carvykti for multiple myeloma, with Q3 2025 sales reaching $524 million and analysts projecting multi-billion dollar potential by 2030 - Guggenheim's bullish $227 price target reflecting confidence in JNJ's oncology pipeline - Wall Street's "Moderate Buy" consensus with targets ranging from $153 to $230 - Six decades of consecutive dividend increases, with current quarterly payout of $1.30 per share yielding approximately 2.6% We examine why JNJ continues to attract investors seeking stability, income, and resilience despite modest growth expectations. The company's diversified portfolio and strong balance sheet have helped it weather legal challenges and pricing pressures that have impacted the broader healthcare sector. Subscribe now for more financial insights and stock analysis from Quiet Please Productions. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.